Long-term protection after hepatitis B vaccination in people living with HIV

Imagem de Miniatura
Arquivos
art_LARA_Longterm_protection_after_hepatitis_B_vaccination_in_people_2017.PDF (287.78 KB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
FONSECA, Marise Oliveira
Citação
VACCINE, v.35, n.33, p.4155-4161, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Hepatitis B vaccine is important in people living with HIV (PLHIV) since both viruses have the same transmission routes and co-infection has greater morbidity. PLHIV usually have poor response to hepatitis B vaccine. The duration of immunity in PLHIV is unknown. The objective of this study is to evaluate the duration of serological response and clinical protection provided by hepatitis B vaccination in PLHIV. Methods: Retrospective study of a PLHIV cohort primarily vaccinated for hepatitis B virus (HBV) from 2001 to 2002. Markers of infection and protection from HBV were investigated in those individuals who were still attending the outpatient clinic, in sao Paulo, Brazil from 2012 to 2014. Three groups were analyzed. Group 1: adults who responded to primary vaccine series. Group 2: non-responders to primary vaccine series. Group 3: subjects from both Groups 1 and 2 who did not receive any booster doses after seroconversion. Results: A cohort of 121 PLHIV was analyzed for seroconversion and persistence of anti-HBs. The majority were female (54.5%) and mean age was 50.1 years. After 11 years, none of the patients had serologic evidence of HBV infection. Overall, 41/58 (70.7%) of the initial responders (Group 1) had maintained anti-HBs >= 10 mIU/mL. Greater CD4+ values and anti-HBs > 100 mIU/mL at the time of first vaccine series were associated with persistence of anti-HBs. During the time of evaluation, 35/63 (55.6%) of the initial non-responders (Group 2) successfully seroconverted (anti-HBs >= 10 mlU/mL) in response to one or more booster doses. From the time of their seroconversion, 70 of the patients did not receive any further booster doses (Group 3). After 10 years, 54/70 (77.1%) of these individuals has maintained anti-HBs > 10 mIU/mL. Conclusions: Evaluation of long-term immunity for hepatitis B in PLHIV following vaccination showed a strong persistence of anti-HBs and no serologic evidence of HBV infection. Boosters may be effective in PLHIV non-responders to primary vaccination.
Palavras-chave
Hepatitis B vaccine, HIV, Vaccines/immunology, Hepatitis B antibodies, Vaccination, Humoral immunity, Long-term persistence
URI
https://observatorio.fm.usp.br/handle/OPI/21919
Referências
  1. Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
  2. Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
  3. Buskin SE, 2011, WORLD J GASTROENTERO, V17, P1807, DOI 10.3748/wjg.v17.i14.1807
  4. CDC, GUID PREV TREAT OPP
  5. Cornejo-Juarez Patricia, 2006, AIDS Res Ther, V3, P9, DOI 10.1186/1742-6405-3-9
  6. Coutinho Leticia M S, 2008, Rev. Saúde Pública, V42, P992, DOI 10.1590/s0034-89102008000600003
  7. Cruciani M, 2009, VACCINE, V27, P17, DOI [10.1016/j.vaccine.2008.10.040, 10.1016/j.vacine.2008.10.040]
  8. Davies HTO, 1998, BRIT MED J, V316, P989
  9. de Vries-Sluijs TEMS, 2008, J INFECT DIS, V197, P292, DOI 10.1086/524690
  10. Balado MDD, 2010, J INFECT DIS, V202, P362, DOI 10.1086/653707
  11. Fonseca MO, 2005, VACCINE, V23, P2902, DOI 10.1016/j.vaccine.2004.11.057
  12. Hepatitis B, 2009, WKLY EPIDEMIOL REC, V84, P405
  13. Irungu E, 2013, J INFECT DIS, V207, P402, DOI 10.1093/infdis/jis695
  14. Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
  15. Jarrosson L, 2004, VACCINE, V22, P3789, DOI 10.1016/j.vaccine.2004.02.046
  16. Kim JH, 2012, GUT LIVER, V6, P86, DOI 10.5009/gnl.2012.6.1.86
  17. Lao-araya M, 2011, VACCINE, V29, P3977, DOI 10.1016/j.vaccine.2011.03.077
  18. Launay O, 2011, JAMA-J AM MED ASSOC, V305, P1432, DOI 10.1001/jama.2011.351
  19. Lopes VB, 2013, VACCINE, V31, P1040, DOI 10.1016/j.vaccine.2012.12.047
  20. Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1
  21. Mayaphi SH, 2012, SAMJ S AFR MED J, V102, P157
  22. Mena G, 2012, VACCINE, V30, P3703, DOI 10.1016/j.vaccine.2012.03.018
  23. MS/SVS/DVDT, MAN CTR REF IM ESP
  24. Ni JD, 2013, INT J STD AIDS, V24, P117, DOI 10.1177/0956462412472309
  25. Pessoa SD, 2010, VACCINE, V28, P1606, DOI 10.1016/j.vaccine.2009.11.045
  26. Phung BC, 2014, WORLD J GASTROENTERO, V20, P17360, DOI 10.3748/wjg.v20.i46.17360
  27. Pippi F, 2008, HIV MED, V9, P519, DOI 10.1111/j.1468-1293.2008.00598.x
  28. Powis JE, 2012, J INFECT DIS, V205, P1534, DOI 10.1093/infdis/jis243
  29. Rey D, 2000, VACCINE, V18, P1161, DOI 10.1016/S0264-410X(99)00389-8
  30. Rouet F, 2008, CLIN INFECT DIS, V46, P361, DOI 10.1086/525531
  31. Soriano V, 2013, CLIN LIVER DIS, V17, P489, DOI 10.1016/j.cld.2013.05.008
  32. Spradling PR, 2010, J VIRAL HEPATITIS, V17, P879, DOI 10.1111/j.1365-2893.2009.01249.x
  33. Thibault V, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-87
  34. Yang R, 2011, INFECTION, V39, P427, DOI 10.1007/s15010-011-0145-1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05